Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Viz.ai, Inc.
With
Sanofi
Regeneron Pharmaceuticals
Time perspective: This study will collect data prospectively for the Experimental cohort and retrospectively for the Control cohort. There is also an Exploratory cohort which will collect retrospective and prospective data.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged 40 years or older at the time of arrival to the emergency department.
Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \>24 hours in emergency department/urgent care facility or resulting in death.
Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.
You may not be if
Patients on bronchodilator inhaler monotherapy.
Patients leaving against medical advice or expiring during hospitalization.
